The Indian pharma
industry is on a good growth path and is likely to be in the top 10 global
markets by value by 2020. High burden of disease, good economic growth leading
to higher disposable incomes, improvements in healthcare infrastructure and
improved healthcare financing are driving growth in the domestic market.
Pharma companies are growing both
organically and inorganically. Inorganic growth is happening through licensing
and partnerships as high valuation of assets is making acquisitions difficult.
Further, companies are organically improving their operations and productivity
by increasing field force sizes, penetrating in Tier II and III cities and by
expanding their product portfolios.
But now a day’s pharmaceutical
companies are facing trouble during audit. If we look into the growth rate of
Indian pharmaceutical industries, it will fabulous.
The Indian
pharmaceuticals market increased at a Compound annual growth rate (CAGR) of
17.46 per cent during 2005-16 with the market increasing from US$ 6 billion in
2005 to US$ 36.7 billion in 2016 and is expected to expand at a CAGR of 15.92
per cent to US$ 55 billion by 2020.
i am writing an essay for the paper on this particular topic. not only that this post has helped me quite a lot but also it is very informative and helpful to have such information
ReplyDelete